who key our Brian. pleased both to very are joining you, positive Since to us in investor programs. everyone advancing Good we call our is have Thank afternoon on last today’s call. FINTEPLA strides made
or two that X lifelong study to syndrome. their reaching our Phase enrollments second, Lennox-Gastaut patients patient regards present the syndrome in into in to NDA resubmission First with And can LGS. for childhood-onset Dravet the families. agreement difficult in are FDA global and epilepsies These for completing
name a As or FINTEPLA fenfluramine. is candidate ZXXXX brand of our drug the lead reminder,
a the of of constructive for with the seizures NDA with for Dravet syndrome. defined understanding we of end May, a at treatment now FINTEPLA announced, forward the previously FDA re-submission the clear following have and As meeting path associated
chronic specified early concurrence, RTF With the toxicity Refusal studies the agency’s April. are the FDAs in submit able we or to additional in received File the we letter, which without NDA to
It’s In a and important to validation kind upon this the for this and also plan, RTF and implemented were limited with correct resolved unfortunate to submission sets. set results reinforce uploading the para have we of was that clinical the noted incorrect in using determined remediation letter the agreed study an the set date data addition, have re-submitted to portal. FDA issue data the
FDA we September. in communities to treatment by these Dravet on the through as issues in syndrome a and support are the highlighted physician strong caregiver resubmit the track future with Working for and FINTEPLA option potential NDA
for with parallel application European FINTEPLA remains associated to our activities, syndrome I’m that the for In treatment pleased seizures active regulatory under Dravet of report U.S. to regulatory the review.
We in review are NDA XXXX. FINTEPLA currently our in first and United forthcoming the launch for preparing of half resubmission are States the assuming to FINTEPLA priority correspondingly
increase to with investigational tolerated readiness, to-date. community demand the commercial such many patients. data needs, options including understanding more ongoing our also the activities, To treatment have ensure for discussing And of critical better on we and care as generated number new interacting clinicians and efficacious of the treatment a for Dravet continued FINTEPLA
and our XXXX, European in such have December. and Society and as of September, presence European remainder the the As And and Neurology Paediatric the medical Society American significant during of medical meetings, community advocacy conferences at U.S. Child several October these a through programs. Society Neurology level engagements increasing will education in upcoming are in Epilepsy we medical with part physicians meetings, efforts, groups of Zogenix stakeholders, the
of designed control families. both to awareness recently quality draveturgency.com, of the needs including a drug a clinicians website, improved campaign United and and life patients We of seizure their States, launched in better understand also help
quarter to manufacturing, for both our validation scale the commercial the suppliers the drug product. at second we finished finalized during drug Turning product substance and
via already drug pharmacy to been report or up specialty established has in We in Access and supplying EAP. is running are also and patients Expanded to our pleased distribution Program participating
We seen are EAP interest strong extension and the in ongoing encouraged open both and the the participation by community label Dravet have we from our studies.
on More there patients one which at least are Dravet across of XXX valvular programs. have show currently FINTEPLA heart now no XXX profile these these favorable a than In to year, being incidents continues disease. been with treated FINTEPLA patients of safety and total, for
to syndrome move like Lennox-Gastaut now work onto or LGS. in our I’d
to childhood-onset difficult urgently and treat needed. are treatments effective more severe new Another epilepsy which for
As I for and month XXX randomized completed of into that last Study mentioned enrollment earlier, the of last treatment we have XXXX. the period we patients announced
Phase is a As trial subjects in two reminder, between blind years this ongoing trial of global double on placebo-controlled X age. an XX three and
quarter from first We the XXXX. efficacy and will available Study expect in XXXX the be line LGS top data of in safety
patent patents to the portfolio proprietary up patent In issued of to treatment patents and patent in which the strengthened these addition and position two new and of allow global issuance exclusivity development synthetic commercial we’re the of fenfluramine. application patent pleased will the through the our for potentially protections activities, our FINTEPLA for and granting cover allowance intellectual report recent also providing covers XXXX two to of process fenfluramine our notice We property our preparedness manufacture to international proprietary to protection regulatory recent for are that U.S. safe use marketing U.S. portfolio application epilepsy combination one after bring beyond. we seven, and with use patents. The U.S. issued
X childhood-onset plans open syndrome. need, to epilepsy discussed input in in Phase we several including response a label FINTEPLA for FINTEPLA for we Boards. need a potential syndrome. to FINTEPLA of treatments we the have We study year, severe address Dravet of randomized syndromes, to In study stress the epilepsies to in Advisory this prepare initiate start study, controlled this to of Earlier exploratory new the for members Dravet and for urgent initiate to decided refractory several this engaged
look year information to to and the We later expect further months. forward this study coming this providing begin in
we made multiple Dravet and intellectual our conclusion, good the programs position or both FINTEPLA. and have developments, In global in LGS proprietary for regulatory commercial strengthened property medical for areas and affairs progress
ahead Looking the to are in preparing the the remainder of in syndrome FINTEPLA resubmission year, for NDA for we Dravet September.
FINTEPLA We in to the are initiate program conditions the In next epilepsy under Dravet several anticipate childhood-onset severe LGS first addition, our a Europe. remains our year. in application of of Phase later X on with syndrome track MAA line preparing moreover in top results and we in quarter review And year. remain in study
I’ll that, his the financials. over review call Mike? turn now With the to for Mike of
